Patents Examined by Marcia S. Noble
  • Patent number: 10752881
    Abstract: The present invention comprises methods and compositions related to trans-differentiating differentiated cells, the methods comprising bringing said cells into contact with a polypeptide or a nucleic acid encoding said polypeptide.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: August 25, 2020
    Assignee: Helmholtz Zentrum München—Deutsches Forschungszentrum Für Gesundheit Und Umwelt (GMBH)
    Inventors: Sergio Gascón Jiménez, Magdalena Götz
  • Patent number: 10745670
    Abstract: A culture medium is provided which is capable of establishing expanded potential stem cell (EPSC) lines which resemble naive or ground state ES cells, but are also able to differentiate into placenta trophoblasts and the embryo proper. Methods are provided using the medium for the in vitro conversion and maintenance of cells, including pluripotent cells into EPSCs.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: August 18, 2020
    Assignee: GENOME RESEARCH LIMITED
    Inventors: Pentao Liu, David Ryan, Xuefei Gao, Wei Wang, Jian Yang
  • Patent number: 10729112
    Abstract: The present invention relates to a transgenic pig comprising a mutated IAPP gene and displaying a phenotype associated with diabetes. The invention also relates to a transgenic blastocyst, embryo, fetus, donor cell and/or cell nucleus derived from said transgenic pig. The invention further relates to use of the transgenic pig as a model system for studying therapy, treatment and/or prevention of diabetes.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: August 4, 2020
    Assignee: Aarhus Universitet
    Inventors: Lars Bolund, Yonglun Luo
  • Patent number: 10723998
    Abstract: Disclosed is a use of ethyl p-methoxycinnamate and derivatives thereof in preparing drugs, culture media, regulating agents or cosmetic and skin caring products for maintaining self-renewal and pluripotency of stem cells. The stem cells comprise adult stem cells, embryonic stem cells and induced pluripotent stem (iPS) cells. Also disclosed is a use of ethyl p-methoxycinnamate and the derivatives thereof in in-vitro amplification of stem cells and preparation of induced pluripotent stem (iPS) cells and a use of ethyl p-methoxycinnamate and the derivatives thereof in preparing drugs for treating cell deletion or injury diseases.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: July 28, 2020
    Assignee: Northeast Normal University
    Inventors: Yongli Bao, Yuxin Li, Hongshuang Qin
  • Patent number: 10717991
    Abstract: The present invention relates to a transgenic pig in which an immune rejection response is suppressed during xenotransplantation, wherein a gene coding for heme oxygenase-1 (HO-1) and a gene coding for tumor necrosis factor receptor 1-Fc (TNFR1-Fc) are simultaneously expressed and a gene coding for ?-1,3-galactosyltransferase (GGTA1) is knocked out; and a method for producing the same.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: July 21, 2020
    Assignees: CHONG KUN DANG PHARMACEUTICAL CORP., SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Byeong Chun Lee, Curie Ahn, Geon A Kim, Su Cheong Yeom, Su Jin Kim, Bumrae Cho, Eun Mi Lee, Sang Hoon Lee, In Chang Hwang, Hye Jin Hong
  • Patent number: 10716866
    Abstract: Provided is a pharmaceutical composition for preventing or treating neuronal diseases comprising, as an active ingredient, an exon 2-deleted AIMP2 variant (AIMP2-DX2) gene or a vector comprising the gene, and a method for treating neuronal diseases in animals other than humans, comprising administering the same to a subject in need of treatment. The pharmaceutical composition comprising, as an active ingredient, a AIMP2-DX2 gene or a vector comprising the gene has the effects of apoptosis inhibition, dyskinesia amelioration and oxidative stress inhibition and thus can be widely used for preventing and treating neuronal diseases such as Parkinson's disease and amyotrophic lateral sclerosis.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: July 21, 2020
    Assignee: GENEROATH CO., LTD
    Inventors: Jin Woo Choi, Dong Uk Lee, Ki Hwan Eum
  • Patent number: 10709118
    Abstract: Particular aspects show that the signal peptide remains intact on the mature CD18 molecule on ruminant leukocytes rendering these cells susceptible to cytolysis by Lkt. Comparative amino acid sequence analysis of the signal peptide of CD18 of eight ruminants and five non-ruminants revealed that the ruminant CD18 signal peptides contain ‘cleavage-inhibiting’ glutamine (Q), compared to ‘cleavage-conducive’ glycine in non-ruminants, at position ?5 relative to the cleavage site. Mutagenesis of Q at position ?5 of the bovine CD18 signal peptide to G resulted in the abrogation of Lkt-mediated cytolysis of transfectants expressing bovine CD18 carrying the Q(?5)G mutation. Provided is novel technology to clone cattle and other ruminants expressing CD18 without the signal peptide on their leukocytes, providing ruminants that are less susceptible to M. haemolytica. Methods for treating conditions and/or diseases associated with M. haemolytica (e.g.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: July 14, 2020
    Assignee: Washington State University
    Inventors: Subramaniam Srikumaran, Sudarvili Shanthalingam
  • Patent number: 10687519
    Abstract: A transgenic animal is provided. In certain embodiments, the transgenic animal comprises a genome comprising: an immunoglobulin light chain locus comprising: a) a functional immunoglobulin light chain gene comprising a transcribed variable region encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of 2 to 5 different amino acids; and ii. a light chain framework; and, operably linked to the functional immunoglobulin light chain gene: b) a plurality of pseudogene light chain variable regions each encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of the same 2 to 5 different amino acids as the CDRs of the functional gene; and ii. a light chain framework that is identical in amino acid sequence to the light chain framework of the transcribed variable region.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: June 23, 2020
    Assignee: CRYSTAL BIOSCIENCE INC.
    Inventors: William Don Harriman, Robert Etches, Philip A. Leighton
  • Patent number: 10689624
    Abstract: [Problem to be Solved] To provide a compound for removing pluripotent cells from a cell population potentially containing the pluripotent cells. [Solution] A polyphenylalanine derivative is contacted with a cell population of interest.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: June 23, 2020
    Assignee: Kyoto University
    Inventors: Hirohide Saito, Yi Kuang
  • Patent number: 10683486
    Abstract: Methods for producing hepatocytes from pluripotent human stem cells are disclosed herein. The stem cells are plated on a cell culture substrate comprising two laminins. The stem cells are then exposed to different cell culture mediums to induce differentiation. The resulting hepatocytes have higher metabolic capacity compared to hepatocytes cultured on different substrates.
    Type: Grant
    Filed: October 29, 2016
    Date of Patent: June 16, 2020
    Assignees: BIOLAMINA AB, THE UNIVERSITY OF EDINBURGH
    Inventors: Louise Kristina Hagbard, Carl Gunnar Jesper Ericsson, Katherine Rachel Cameron, David Colin Hay, Stuart John Forbes, Hassan Rashidi
  • Patent number: 10675303
    Abstract: The present invention is directed to methods of inhibiting cancer cell growth or proliferation by contacting the cancer cell with an extracellular matrix (ECM) composition. Also provided are methods of delivering a chemotherapeutic agent to a cancer cell by contacting a cancer cell with an extracellular matrix composition containing a chemotherapeutic agent. Also provided are compositions containing ECM and a chemotherapeutic agent.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: June 9, 2020
    Assignee: Adaptive Biologix, Inc.
    Inventors: Gail K. Naughton, Emmett Pinney
  • Patent number: 10662410
    Abstract: The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: May 26, 2020
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 10662409
    Abstract: In some embodiments, the present invention provides methods including the steps of providing one or more human somatic cells, causing transient increased expression of OCT4, KLF4, SOX2, and cMYC in the somatic cells forming modified somatic cells, providing a plurality of inactivated embryonic fibroblasts, associating the modified somatic cells with the inactivated embryonic fibroblasts in a culture media comprising 20% KO DMEM xeno-free serum replacement and at least 15 ng/ml recombinant bFGF to form human induced neural stem cells.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: May 26, 2020
    Assignee: Trustees of Tufts College
    Inventors: Dana Cairns, David L. Kaplan
  • Patent number: 10640748
    Abstract: The present invention relates to methods of treating or ameliorating certain neurodegenerative disorders (namely, dysmyelinating and demyelinating disorders) in patients in need of such treatment or amelioration. The invention provides methods of treating or ameliorating a patient in need of such treatment and includes the administration to the patient of: (a) thyroid hormones or thyroid hormone analogues; (b) cell replacement therapies involving the use of homogenous Oligodendrocyte Precursor Cells derived from embryonic stem cells that have been treated with thyroid hormones or thyroid hormone analogues; (c) gene therapy to correct mutated genes in vivo; or (d) a combination of two or more of (a), (b) and (c). The invention also provides compositions and formulations of thyroid hormones and thyroid hormone analogues for use in treating or ameliorating such disorders.
    Type: Grant
    Filed: December 24, 2015
    Date of Patent: May 5, 2020
    Assignee: NEUORPHAN PTY LTD
    Inventors: Steven Petratos, Michael Farzad Azari, Jae Young Lee, Min Joung Kim
  • Patent number: 10639335
    Abstract: An object of the present invention is to provide a novel medical application for use in regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating myocardial infarction, and particularly serious massive myocardial infarction and heart failure associated therewith, that contains pluripotent stem cells positive for SSEA-3 isolated from biological mesenchymal tissue or cultured mesenchymal cells. The cell preparation of the present invention is based on a cardiac tissue regeneration mechanism by which Muse cells are made to selectively accumulate in damaged myocardial tissue and differentiate into cardiac muscle in that tissue as a result of intravenous administration of Muse cells to a subject presenting with the aforementioned disorders.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: May 5, 2020
    Assignees: CLIO, INC., GIFU UNIVERSITY, TOHOKU UNIVERSITY
    Inventors: Masanori Yoshida, Shinya Minatoguchi, Mari Dezawa
  • Patent number: 10626368
    Abstract: Provided is a method for producing cerebral cortex neurons from pluripotent stem cells. Provided is a method for producing cerebral cortex neurons from pluripotent stem cells, comprising (i) a step of performing a suspension culture of pluripotent stem cells in a culture medium containing a TGF? inhibitor, bFGF, a Wnt inhibitor, and a BMP inhibitor, (ii) a step of performing a suspension culture of the cells obtained in the step (i) in a culture medium containing a Wnt inhibitor and a BMP inhibitor, and (iii) a step of further culturing the cells obtained in the step (ii).
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: April 21, 2020
    Assignee: KYOTO UNIVERSITY
    Inventors: Jun Takahashi, Makoto Motono, Yoshihiko Ioroi
  • Patent number: 10596273
    Abstract: Novel adeno-associated virus (AAV) vectors in nucleotide and amino acid forms and uses thereof are provided. The isolates show specific tropism for certain target tissues, such as blood stem cells, liver, heart and joint tissue, and may be used to transduce stem cells for introduction of genes of interest into the target tissues. Certain of the vectors are able to cross tightly controlled biological junctions, such as the blood-brain barrier, which open up additional novel uses and target organs for the vectors, providing for additional methods of gene therapy and drug delivery.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: March 24, 2020
    Assignee: CITY OF HOPE
    Inventors: Saswati Chatterjee, Laura Jane Smith, Kamehameha Wong
  • Patent number: 10590383
    Abstract: Methods are provided, in some aspects, for differentiating pluripotent cells into midbrain dopaminergic (DA) neurons using a mono-SMAD inhibition or inhibition of SMAD signaling with only one SMAD inhibitor. In some embodiments, mono-SMAD inhibition utilizes a single inhibitor of bone morphogenic protein (BMP) for differentiating pluripotent cells into midbrain DA neurons.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: March 17, 2020
    Assignee: FUJIFILM Cellular Dynamics, Inc.
    Inventors: Christopher W. McMahon, Lauren E. Little, Wen Bo Wang, Nathaniel A. Elliott
  • Patent number: 10584314
    Abstract: An object of the present invention is to provide a method of inducing pluripotent stem cells to differentiate into clinically applicable retinal ganglion cells. The present invention provides a method for inducing pluripotent stem cells to differentiate into retinal ganglion cells that can be used for clinical application. Such method is a method for producing retinal ganglion cells with elongated axons comprising the following steps: (a) a step of inducing pluripotent stem cells to differentiate into retinal progenitor cells via floating culture; (b) a step of inducing the retinal progenitor cells obtained in step (a) to differentiate into retinal ganglion cells via floating culture; and (c) a step of allowing axons to elongate via adhesion culture of the retinal ganglion cells obtained in step (b).
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: March 10, 2020
    Assignees: NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT, SENJU PHARMACEUTICAL CO., LTD.
    Inventors: Noriyuki Azuma, Taku Tanaka, Tadashi Yokoi
  • Patent number: 10584316
    Abstract: Described here are three-dimensional microenvironment niches prepared from biomaterial compositions that support growth and self renewal of stem cells. The invention also provides methods for inducing pluripotency in a somatic cell using chemical compounds, as well as methods for screening for compounds that can induce pluripotency in a somatic cell.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: March 10, 2020
    Inventor: Babak Esmaeli-Azad